A detailed history of Baker Bros. Advisors LP transactions in Igm Biosciences, Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 4,090,316 shares of IGMS stock, worth $72.9 Million. This represents 0.37% of its overall portfolio holdings.

Number of Shares
4,090,316
Previous 4,088,322 0.05%
Holding current value
$72.9 Million
Previous $39.5 Million 28.77%
% of portfolio
0.37%
Previous 0.5%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$6.51 - $11.47 $12,980 - $22,871
1,994 Added 0.05%
4,090,316 $28.1 Million
Q1 2024

May 15, 2024

BUY
$8.68 - $17.36 $3.45 Million - $6.9 Million
397,311 Added 10.76%
4,088,322 $39.5 Million
Q4 2023

Feb 14, 2024

BUY
$3.94 - $8.79 $2.1 Million - $4.69 Million
533,247 Added 16.89%
3,691,011 $30.7 Million
Q3 2023

Nov 14, 2023

BUY
$6.66 - $10.64 $3,689 - $5,894
554 Added 0.02%
3,157,764 $26.4 Million
Q2 2023

Aug 14, 2023

BUY
$8.86 - $14.0 $4,908 - $7,756
554 Added 0.02%
3,157,210 $29.1 Million
Q1 2023

May 15, 2023

BUY
$13.74 - $25.76 $7,611 - $14,271
554 Added 0.02%
3,156,656 $43.4 Million
Q1 2021

May 17, 2021

BUY
$71.56 - $121.23 $802,187 - $1.36 Million
11,210 Added 0.36%
3,156,102 $242 Million
Q4 2020

Feb 16, 2021

BUY
$47.41 - $115.03 $21,144 - $51,303
446 Added 0.01%
3,144,892 $278 Million
Q3 2020

Nov 16, 2020

BUY
$43.0 - $84.01 $9,589 - $18,734
223 Added 0.01%
3,144,446 $232 Million
Q2 2020

Aug 14, 2020

BUY
$51.3 - $75.21 $11,439 - $16,771
223 Added 0.01%
3,144,223 $230 Million
Q3 2019

Nov 14, 2019

BUY
$17.75 - $24.3 $55.8 Million - $76.4 Million
3,144,000 New
3,144,000 $55.8 Million

Others Institutions Holding IGMS

About IGM Biosciences, Inc.


  • Ticker IGMS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,969,000
  • Market Cap $517M
  • Description
  • IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...
More about IGMS
Track This Portfolio

Track Baker Bros. Advisors LP Portfolio

Follow Baker Bros. Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Baker Bros. Advisors LP with notifications on news.